Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is studying induction nimotuzumab plus gemcitabine and carboplatin
followed by surgery to see how well it works in treating patients with unresectable stage III
squamous cell lung carcinoma.